INCR:NASDAQIntercure Ltd. Analysis

InterCure Ltd. trades at $0.88, comfortably above its 20‑day (0.84) and 50‑day (0.80) SMAs but still well below the 200‑day SMA (1.16), indicating a short‑term bounce within a longer‑term downtrend. The RSI sits at 59.5 and the MACD line is marginally above its signal, both pointing to modest bullish momentum, while the price is perched near the upper end of its technical range (support 0.77, resistance 0.93). Valuation metrics are strikingly low – a price‑to‑book of 0.12 and a negative PE reflect deep discounting, yet the company posted NIS 270 million of revenue and generated positive operating cash flow of NIS 17 million in its latest results, suggesting a potential turnaround. However, profitability remains weak with a net loss of NIS 37 million and a max drawdown of –57.8%, and the stock suffers from decreasing volume and a high 30‑day volatility of 59%, underscoring significant market risk. Overall, the stock appears undervalued on a balance‑sheet basis but is burdened by earnings weakness, liquidity constraints, and sector‑specific regulatory uncertainty.